Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.

Mohammad S Hossain; Wayne A Harris; Sarah W Myers; Mojtaba Akhtari; Amelia A Langston; Edmund K. Waller

Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.

Mohammad S Hossain, Wayne A Harris, Sarah W Myers, Mojtaba Akhtari, Amelia A Langston, Edmund K. Waller

Medicine

Research output: Contribution to journal › Conference article › peer-review

Original language	American English
Journal	Blood
Volume	114
State	Published - Nov 20 2009

Disciplines

Virology
Immunology and Infectious Disease
Medicine and Health Sciences

OpenUrl availability

Full text

Cite this

@article{4915c5c10cf8482bac827cd9d81b1cf3,

title = "Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.",

author = "Hossain, \{Mohammad S\} and Harris, \{Wayne A\} and Myers, \{Sarah W\} and Mojtaba Akhtari and Langston, \{Amelia A\} and Waller, \{Edmund K.\}",

note = "Opportunistic CMV infections remain a major cause of morbidity and mortality in allogeneic hematopoetic stem cell transplant (HSCT) recipients, with prolonged periods of viremia associated with cytopenia and life-threatening end-organ infections. Although CMV infection in allogeneic HSCT recipients may be controlled using anti-viral drugs, re-occurrence of viremia when drug therapy is stopped is common, and the emergence of drug resistant viral strains may render the anti-viral agents ineffective.",

year = "2009",

month = nov,

day = "20",

language = "American English",

volume = "114",

journal = "Blood",

}

TY - JOUR

T1 - Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.

AU - Hossain, Mohammad S

AU - Harris, Wayne A

AU - Myers, Sarah W

AU - Akhtari, Mojtaba

AU - Langston, Amelia A

AU - Waller, Edmund K.

N1 - Opportunistic CMV infections remain a major cause of morbidity and mortality in allogeneic hematopoetic stem cell transplant (HSCT) recipients, with prolonged periods of viremia associated with cytopenia and life-threatening end-organ infections. Although CMV infection in allogeneic HSCT recipients may be controlled using anti-viral drugs, re-occurrence of viremia when drug therapy is stopped is common, and the emergence of drug resistant viral strains may render the anti-viral agents ineffective.

PY - 2009/11/20

Y1 - 2009/11/20

UR - http://www.bloodjournal.org/content/114/22/1165?sso-checked=true

M3 - Conference article

VL - 114

JO - Blood

JF - Blood

ER -

Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.

Disciplines

OpenUrl availability

Other files and links

Cite this